Single-center retrospective cohort
6 evidence topics · 2 sources
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using time to treatment failure as an effectiveness endpoint
Endpoint rationale
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Reported outcomes by disease status
| Measure | Quoted value |
|---|---|
| Complete response, refractory disease: cases | “13” |
| Complete response, recurrent disease: cases | “11” |
| Time to treatment failure, refractory disease: months | “7.9” |
| Time to treatment failure, recurrent disease: months | “14.2” |
| Overall survival, refractory disease: months | “25” |
| Overall survival, recurrent disease: months | “32.4” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Severe pulmonary and hepatic adverse events
Study limitations
Summary
The cohort included 35 participants treated at one institution between 2020 and 2025. Its retrospective design and separate recurrent and refractory groups limit causal interpretation of differences in treatment-failure and survival estimates. There was no randomized comparator in the reported design.